These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1446048)

  • 21. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients.
    Lee JH; Glick HA; Hayman JA; Solin LJ
    J Clin Oncol; 2002 Jun; 20(11):2713-25. PubMed ID: 12039934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model.
    Hillner BE
    Recent Results Cancer Res; 1993; 127():277-84. PubMed ID: 8502826
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer.
    Bonastre J; Marguet S; Lueza B; Michiels S; Delaloge S; Saghatchian M
    J Clin Oncol; 2014 Nov; 32(31):3513-9. PubMed ID: 25287824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL; Marchetti M; Barosi G
    J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
    Jacobs VR; Kates RE; Kantelhardt E; Vetter M; Wuerstlein R; Fischer T; Schmitt M; Jaenicke F; Untch M; Thomssen C; Harbeck N
    Breast Cancer Res Treat; 2013 Apr; 138(3):839-50. PubMed ID: 23568480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant therapy of node-negative breast cancer.
    Hall PD; Lesher BA; Hall RK
    Ann Pharmacother; 1995 Mar; 29(3):289-98. PubMed ID: 7606076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer.
    Levine MN; Gafni A; Markham B; MacFarlane D
    Ann Intern Med; 1992 Jul; 117(1):53-8. PubMed ID: 1596048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulations model for predicting survival in women receiving adjuvant therapy for early breast cancer.
    Ibrahim EM; Nassim FM; Ibrahm RE
    Cancer J Sci Am; 1996; 2(4):234-40. PubMed ID: 9166538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Rocchi A; Verma S
    Support Care Cancer; 2006 Sep; 14(9):917-27. PubMed ID: 16596419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for Korean women with breast cancer: retrospective cohort study of the Korean breast cancer society database.
    Yang JJ; Park SK; Cho LY; Han W; Park B; Kim H; Lee KS; Hahn SK; Cho SI; Ahn SH; Noh DY;
    Clin Ther; 2010 Jun; 32(6):1122-38. PubMed ID: 20637966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of oncotype DX recurrence score in the management of breast cancer cases.
    Nguyen MT; Stessin A; Nagar H; D'Alfonso TM; Chen Z; Cigler T; Hayes MK; Shin SJ
    Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
    Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
    J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of the 21-gene breast cancer assay in Mexico.
    Bargalló-Rocha JE; Lara-Medina F; Pérez-Sánchez V; Vázquez-Romo R; Villarreal-Garza C; Martínez-Said H; Shaw-Dulin RJ; Mohar-Betancourt A; Hunt B; Plun-Favreau J; Valentine WJ
    Adv Ther; 2015 Mar; 32(3):239-53. PubMed ID: 25740550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
    Chilcott J; Lloyd Jones M; Wilkinson A
    Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects.
    Au HJ; Golmohammadi K; Younis T; Verma S; Chia S; Fassbender K; Jacobs P
    Breast Cancer Res Treat; 2009 Apr; 114(3):579-87. PubMed ID: 18443903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.